First- and second-line therapy for metastatic urothelial carcinoma of the bladder - Wikidata - wikimedia - TriplyDB

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

http://www.wikidata.org/entity/Q34541463

about

Emerging critical role of molecular testing in diagnostic genitourinary pathology Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Expression proteomics study to determine metallodrug targets and optimal drug combinations.δ-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway.Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Urothelial carcinoma management in elderly or unfit patients.The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis.Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells

P2860

Q27021371-2DF92CE7-3D9E-412B-8B4B-4ADFEE50B331 Q33411581-3E9E4021-CD4C-496A-9FF8-02B9F55C06C1 Q33685955-3D265933-E7E1-4F5B-BD06-3AE196AB2F6B Q35301664-E7131682-8155-4C79-800F-0AED7D2408F4 Q35956711-EA548EB2-BA7A-4F65-80FA-28A485B8D177 Q36143699-CE417CA4-B3F2-4B2F-B469-09B4BF629A1D Q36145468-27C81842-F94A-4BDB-9F68-57049D0FA681 Q36367297-2C8FD81F-4A27-48E5-BD3E-C64D3C899B13 Q36947812-B2BE7B3E-9019-45AD-B07F-CAB171CCA628 Q37030514-ED1E732E-6B35-4627-967F-A2511DA762F2 Q37932541-A9E47757-8842-414C-922E-43EE850B22F0 Q38685278-59C9769C-892D-44BE-AD36-7E8707B49426 Q41339763-96B5ED76-E20E-4F58-A222-C53DA4E9FA23 Q44373064-C93257D6-BC4A-4FFA-9C60-077CAC06EBA3 Q58788836-6048E46E-EF74-4562-ABC8-115B1A04DA36

P2860

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

http://www.wikidata.org/entity/Q34541463

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@ast

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@en

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@nl

type

label

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@ast

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@en

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@nl

prefLabel

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@ast

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@en

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@nl

P1433

Q34541463-47D7FDEC-02CE-472D-9A23-4D034740B5A8

P1476

Q34541463-13265D1E-5C76-4CBB-874C-3B84FBE86074

P2093

Q34541463-1CCF7353-FB8B-4B81-AB28-29EA12E15A16

Q34541463-697D81F1-C0F3-4114-8C1E-65E335FB7010

Q34541463-A89D6542-EDF4-456F-A33C-18BF4BAD7A86

P2860

Q34541463-00F6DBDB-D1D6-426F-9965-31C2A3A6BF9C

Q34541463-037A1902-1044-46BF-94DE-F234E731A466

Q34541463-04B3A1FD-E372-4889-BFE9-12A8D20338CA

Q34541463-0949B277-0F42-4C55-B1D4-9C10461D7A17

Q34541463-0C8A9072-50BA-4FE6-8EED-CE1260D96719

Q34541463-0CAB4198-5A02-40AF-BDFE-A09B4FC3963A

Q34541463-0E1228CB-5B4C-44BC-BD23-9CF18A752413

Q34541463-0F896A82-575F-4A78-B14E-33554DF712BF

Q34541463-1612DA7E-C5B4-4D47-8968-01FFAAF80C39

Q34541463-1656AD25-179F-402D-ADEA-5A22FE32D37B

P304

Q34541463-A7CE934F-3A71-4312-A079-631E67CEC8C2

P31

Q34541463-A76BCBC8-3523-4FC3-AC1A-566A9F840242

P356

Q34541463-2FDDE847-E93D-4436-855A-367C950FB1D6

P433

Q34541463-67020FB3-C8BA-4ACD-A2F2-32B68B7739E8

P478

Q34541463-364B509F-FE85-47A6-A88E-273E9C3CA132

P577

Q34541463-46816186-FDC6-4761-B309-356B81812CEE

P5875

Q34541463-074A7AE0-FF3E-4DBE-9BB3-016533D21997

P698

Q34541463-F5810811-6B68-44BB-ADF0-B035BCCF43DD

P932

Q34541463-A7E434A0-0A2F-4A9B-B589-0203D9B7DF8B

P356

P1433

Current Oncology

P1476

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

@en

P2093

F A Yafi

http://www.w3.org/2001/XMLSchema#string

S North

http://www.w3.org/2001/XMLSchema#string

W Kassouf

http://www.w3.org/2001/XMLSchema#string

P2860

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Cancer statistics, 2009

Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.

P304

e25-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.V18I1.695

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49845620

http://www.w3.org/2001/XMLSchema#string

P698

21331269

http://www.w3.org/2001/XMLSchema#string

P932

3031362

http://www.w3.org/2001/XMLSchema#string